NCT05641935RecruitingPhase 2
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
Multi-Modality Detection of RCC Recurrence Post Ablation
Source: ClinicalTrials.gov · Last updated 17 Feb 2026
Brief summary (registry, in English)
This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 210 (estimated)
- First submitted
- 29 Nov 2022
- Start date
- 3 Nov 2022
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- john eisenbrey
- Diseases
- Kidney cancer
- NCT number
- NCT05641935
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 210
- From 3 Nov 2022 to the primary completion date, 31 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable
- Patients with known sensitivities to the components of Lumason
Who the study is looking for
- Previously received cryotherapy or microwave therapy of RCC
- Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy
- Have previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 4 weeks of the CEUS study
- Be at least 18 years of age
- Be medically stable
- If a female of child-bearing age, must have a negative pregnancy test
- Have signed Informed Consent to participate in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sidney Kimmel Cancer Center at Thomas Jefferson University Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.